June 3, 2021

Vaccine Effectiveness of the BNT162b2 MRNA COVID-19 Vaccine against RT-PCR Confirmed SARS-CoV-2 Infections Hospitalisations and Mortality in Prioritised Risk Groups

Category: Article Summary

Topic: Vaccines and Immunity

Keywords (Tags): vaccine efficacy

• [Pre-print, not peer-reviewed] Effectiveness of the Pfizer-BioNTech vaccine >7 days after the second dose ranged between 53-86% in preventing SARS-CoV-2 infection, ≥75% in preventing COVID-19 hospitalizations, and ≥89% in preventing COVID-19 deaths in a nationwide cohort study of high-risk groups in Denmark including long term care facility (LTCF) residents, individuals aged ≥65 years requiring personal care at home, individuals aged ≥85 years, healthcare workers, and individuals with comorbidities (n=864,096). Effectiveness against infection 0-7 days after the second dose ranged from 46-71%. Vaccine effectiveness against all COVID-19 related outcomes was lowest among LTCF residents.

Emborg et al. (June 2, 2021). Vaccine Effectiveness of the BNT162b2 MRNA COVID-19 Vaccine against RT-PCR Confirmed SARS-CoV-2 Infections Hospitalisations and Mortality in Prioritised Risk Groups. Pre-print downloaded Jun 3 from https://doi.org/10.1101/2021.05.27.21257583